文献速递核素与放射性配体治疗肿瘤 PET/CT

放射性配体治疗在肺神经内分泌肿瘤患者中的疗效与安全性:一项系统综述

Radioligand Therapy in Patients with Lung Neuroendocrine Tumors: A Systematic Review on Efficacy and Safety.
PubMed 文献 · Semin Nucl Med · 2024-05-28

该系统综述遵循PRISMA指南检索MEDLINE和EMBASE截至2023年3月31日的英文文献,纳入27项研究共786例肺神经内分泌肿瘤患者。汇总分析显示客观缓解率25.6%、疾病控制率75.6%,中位无进展生存期平均20个月、总生存期平均45个月。放射性配体治疗的不良反应以血液学为主且多为1/2级可控,镥-177的安全性优于钇-90。

要点

  • 肺神经内分泌肿瘤患者接受放射性配体治疗的汇总客观缓解率为25.6%,疾病控制率为75.6%。
  • 中位无进展生存期平均20个月,总生存期平均45个月。
  • 不良反应以血液学1/2级为主且可控,镥-177的安全性优于钇-90。

核心结论

  • 研究结果支持放射性配体治疗在肺神经内分泌肿瘤中的有效性,为生长抑素受体阳性的晚期患者带来希望。
  • 尽管识别疗效预测因素仍具挑战,放射性配体治疗在既往治疗后仍保持疗效,典型类癌的缓解略优于非典型类癌。

研究设计与样本

  • 遵循PRISMA指南对MEDLINE和EMBASE数据库进行系统综述,检索截至2023年3月31日的英文文献。
  • 纳入标准为涉及肺神经内分泌肿瘤放射性配体治疗并评估疗效与安全性的研究。
  • 共27项研究符合标准,合计786例患者。

主要发现

  • 汇总分析显示客观缓解率为25.6%,疾病控制率为75.6%。
  • 中位无进展生存期平均为20个月,总生存期平均为45个月。
  • 影响缓解的因素包括肿瘤负荷、既往治疗、18F-FDG PET扫描摄取及组织学变异型。
  • 放射性配体治疗的不良反应以血液学为主,多为1/2级且可控,镥-177的安全性优于钇-90。
  • 放射性配体治疗在既往治疗后仍保持疗效,典型类癌的缓解略优于非典型类癌。

关键数值与推荐

  • 临床指南将放射性配体治疗列为肺神经内分泌肿瘤的三线或四线选择。
  • 汇总客观缓解率为25.6%,疾病控制率为75.6%。
  • 中位无进展生存期平均为20个月,总生存期平均为45个月。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为需要前瞻性试验来确定放射性配体治疗的明确疗效及其在肺神经内分泌肿瘤治疗格局中的地位。

局限性

  • 近年的多项研究主要为回顾性研究。
  • 识别疗效预测因素仍具挑战。
  • 需要前瞻性试验来确定放射性配体治疗的明确疗效及其在肺神经内分泌肿瘤治疗格局中的地位。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neuroendocrine neoplasms (NENs), arising from various sites, present therapeutic challenges. Radioligand therapy (RLT) is effective for unresectable/metastatic NENs with increased somatostatin receptor uptake. While evidence supports RLT's efficacy in midgut NETs, its role in lung NETs remains underexplored. Clinical guidelines place RLT as a third or fourth-line option in this setting. However, in the last years several studies investigated mainly retrospectively effectiveness and safety of RLT in lung NET. The aim of this review is to assess the efficacy and safety of RLT in patients with lung NETs. Following PRISMA guidelines, a systematic review of MEDLINE and EMBASE databases retrieved English articles until March 31, 2023. Inclusion criteria encompassed studies involving RLT in lung NETs with efficacy and safety assessments. Twenty-seven studies met the criteria, totaling 786 patients. The pooled analysis revealed a 25.6% objective response rate and 75.6% disease control rate. Median progression-free survival averaged 20 months, while overall survival averaged 45 months. Factors affecting response included tumor burden, prior treatments, 18F-FDG PET scan uptake, and histological variants. RLT exhibited manageable grade 1/2 adverse effects, predominantly hematological, with Lu177 demonstrating a more favorable profile than Y90. The findings support RLT's effectiveness in lung NETs, offering hope for advanced SSTR-positive patients. Although identifying predictive factors for response remains challenging, RLT retained efficacy even after prior therapies and typical carcinoids displayed a slightly better response than atypical ones. Prospective trials are imperative to establish RLT's definitive efficacy and its place in the therapeutic landscape for lung NETs.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Malandrino P, Feola T, Mikovic N, et al. Radioligand Therapy in Patients with Lung Neuroendocrine Tumors: A Systematic Review on Efficacy and Safety. Semin Nucl Med. 2024. PMID: 38811266. doi:10.1053/j.semnuclmed.2024.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。